Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28308019 | 0.87 | SMN1; SMN2 (0.81) | SMN1; SMN2ATMLMNATSHRNPC1 | |
| SCHEMBL5928664 | 0.84 | SMN1; SMN2 (0.92) | SMN1; SMN2ATMLMNATSHRNPC1 | |
| SCHEMBL5928772 | 0.83 | NPC1 (0.64) | SMN1; SMN2ATMLMNATSHRNPC1 | |
| SCHEMBL28308015 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2ATMLMNATSHRNPC1 | |
| SCHEMBL5928915 | 0.83 | NPC1 (0.72) | SMN1; SMN2ATMLMNATSHRNPC1 | |
| SCHEMBL28677827 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2ATMLMNATSHRNPC1 | |
| SCHEMBL28308021 | 0.82 | LMNA (1.00) | SMN1; SMN2ATMLMNATSHRNPC1 | |
| SCHEMBL28307048 | 0.82 | LMNA (1.00) | SMN1; SMN2ATMLMNATSHRNPC1 | |
| SCHEMBL14743414 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2ATMLMNATSHRNPC1 | |
| SCHEMBL28308020 | 0.82 | NPC1 (0.66) | SMN1; SMN2ATMLMNATSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6461417-B1 | Ink compositions | XEROX CORPORATION | 2002-10-08 | — | — | US | claimed |
| US-6117223-A | Hot melt inks containing polyketones | XEROX CORPORATION (US) | 2000-09-12 | — | — | US | claimed |
| CN-110041306-B | 4-hydroxy-2-quinolone-N- (4-quinazolinone) -3-carboxamide derivatives | 中国医学科学院药物研究所 | 2022-01-11 | — | — | CN | disclosed |
| CN-110041306-A | 4- hydroxyl -2- quinolone-nitrogen-(4- quinazolinone) -3- carboxamides derivatives | 中国医学科学院药物研究所 | 2019-07-23 | — | — | CN | disclosed |
| US-20180201583-A1 | QUINOLINONE OR QUINAZOLINONE COMPRISING ANTIBIOFILM COMPOSITIONS, COMPOUNDS AND METHODS AND USES RELATING THERETO | UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND (IE) | 2018-07-19 | — | — | US | disclosed |
| US-8962639-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8609674-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2012067824-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122890-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010138828-A2 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7741332-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080058319-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20060229324-A1 | Quinazolin-4-one derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-6461417-B1 | Ink compositions | XEROX CORPORATION | 2002-10-08 | — | — | US | disclosed |
| US-6117223-A | Hot melt inks containing polyketones | XEROX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058319-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | SMN1; SMN2 253/4885ATM 1284/4885LMNA 1121/4885 |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | SMN1; SMN2 253/4885ATM 1284/4885LMNA 1121/4885 |
| US-20060229324-A1 | Quinazolin-4-one derivatives | HPGDS, PTGS1, PTGDR | SMN1; SMN2 4744/4885ATM 3514/4885LMNA 3667/4885 |
| US-20180201583-A1 | QUINOLINONE OR QUINAZOLINONE COMPRISING ANTIBIOFILM COMPOSITIONS, COMPOUNDS AND METHODS AND USES RELATING THERETO | QSOX1, LPO, NQO2 | SMN1; SMN2 4461/4885ATM 2747/4885LMNA 2556/4885 |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | SMN1; SMN2 1516/4885ATM 3249/4885LMNA 741/4885 |
| US-20120122890-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNQ3 | SMN1; SMN2 1749/4885ATM 2827/4885LMNA 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.